Case Report

Introduction

Stromal tumors are the prominent mesenchymal tumors of gastrointestinal tract (GIT) (1). They are more apparent in upper middle age, mostly in 5th and 6th decades. They occur equally in both sexes (1). Gastrointestinal Stromal Tumors (GISTs) are most commonly localized in the stomach (40-70%) and may be found in the intestine (20-32%), colon (10%) and esophagus (5%) (1, 2). They also can be seen in extra-GIT sites like mesentery, omentum and retroperitoneum (2). Major patient complaints regarding GISTs are upper abdominal pain, GIT bleeding and abdominal masses (1). Interstitial cells of Cajal (ICC), which GISTs are thought to originate from, both express tyrosine kinase receptors (c-kit) and stain with CD34 and Vimentin. KIT (CD117) is a transmembrane tyrosine kinase receptor, which is expressed in hematopoietic stem cells, germ cells, mast cells, melanocytes and ICC (2). C-Kit positivity is an important parameter in diagnosis of GIST. Recently, a specific marker, namely discovered on GIST1 (DOG-1), has been discovered for GIST diagnosis. It is shown to be positive on ICCs and gastric surface epithelium. DOG-1 is also expressed in high amounts in KIT mutation-negative cases besides typical GIST cases (3). Immunohistochemical diagnosis of GIST is adopted when mesenchymal tumors stain positive with c-Kit (CD117) and the DOG-1 where the rest of mesenchymal cell markers were negative. Demonstration of CD117 and recently DOG-1 positivity immunohistochemically stands for the standard technique of definitive diagnosis of GIST. CD34 is positive in 70-80% of the cases. Vimentin is diffuse and strong positive in many stromal tumors. SMA is positive in 30-40% and S100 in 5% of GISTs. Staining with desmin is rare (1). Malignant stromal tumors mostly metastasize to liver, peritoneum, lungs and bones (4). Brain and lymph node metastases are unusual (4). No breast metastasis was presented in literature before.

Hereby, we present a case of GIST with liver, bone, lymph node and breast metastases and aimed to discuss its unusual metastatic reviewing literature.

Case Presentation

A 46 year-old woman was referred to us from another health facility with the complaint of back pain. The radiological imaging studies revealed multiple liver metastases with the largest being 5.5 cm in diameter as well as multiple bone involvements. Positron Emission...
Computed Tomography (PET-CT, General Electric Medical System, Milwaukee, USA) demonstrated elevated F-18-fluoro-2-deoxyglucose (FDG) uptake in her left breast in addition to the above-mentioned lesions. Histologic samples taken from abdominal lymph nodes and liver revealed neoplastic lesions composed of cells with prominent hyperchromatic nuclei and spindle-shaped cytoplasm. Immunohistochemistry studies showed strong positive staining with CD117 (Code A4502, Dako, California) in Figure 1 and DOG-1 (Clone SP31, Thermo Scientific, USA) in Figure 2, positive staining with Vimentin (Code-Nr. M 0725, Dako, Denmark) and negative staining with CD34 (Clone QBEnd-10, Dako, Denmark), S100 (Code Z0311, Dako, Denmark) and Desmin (Clone D33, Dako, Denmark) in both liver and lymph node tissues. The patient was diagnosed to have GIST metastasis and therefore was started on imatinib therapy. A control PET-CT obtained on the second month of imatinib treatment demonstrated progression in liver metastases, variable response in bone metastases and partial regression in breast and lymph node metastases. No mass was observed on the physical examination of either of the breasts and the axillae. Breast ultrasound and Magnetic Resonance Imaging showed two small lesions of 5 and 3 mm in close location, which both were thought to be benign.

As for the fact that nuclear regression had been experienced in the left breast under imatinib therapy, tissue diagnosis was planned to rule out malignancy. After the suspected area was marked with needle localization by ultrasound, a wide excisional biopsy was performed. When the specimen of 10x4x4 cm yellow color fatty tissue was examined macroscopically in serial sections, no significant mass was observed in cross-sectional surfaces. Complete sampling of the specimen demonstrated fibroadipose and acinar tissue, as well as two lesions in 3x2 mm and 2x2 mm size composed of spindle cells with prominent nuclei and spindle-shaped cytoplasm (Figure 3). These cells stained strongly with CD117 (Figure 4) and DOG1 (Figure 5) and did not stain with S100, CD34 and SMA (Clone 1A4, Code M0851, Dako, Denmark) immunohistochemically. Microscopy in 10x High Power Magnification (HPM) of these lesions showed 4-5 mitoses. Ki67 (Clone MIB-1, Code M7240, Dako, Denmark) proliferation index was calculated as 3-4%. The case was interpreted as a GIST metastasizing to liver, lymph nodes, bones and breast when evaluated immunohistochemically with its histomorphological findings.

A lumbar MRI scan was obtained due to increased bone pain, which revealed progressive bone metastases. The imatinib dose was doubled; however, she was lost to follow-up. Patient gave orally informed consent.

Discussion and Conclusion

Gastrointestinal stromal tumors (GISTs) can occur anywhere along
the Gastrointestinal tract (GIT) from esophagus to anus besides in omentum, mesentery, retroperitoneum deriving from Interstitial cells of cajal (ICC's) (3, 5). C-kit and DOG-1 positivity in used in the pathologic diagnosis of GISTs (3). Stromal tumors like leiomyomas, leiomyosarcomas, desmoid tumors, mesenteric fibromatosis and fibrosarcomas are considered in differential diagnosis. Tumor size, number of mitosis and localization are the most important prognostic factors of GISTs (1). GISTs are structured as spindle-like in 70%, epithelioid in 20% and mixed in 10%. Spacing signet-ring-like areas can also be observed. Major route of metastases of malignant stromal tumors are liver, peritoneum, lungs and bones (4). Brain and lymph node metastases are extraordinary (4). No breast metastasis of GIST was declared before. There are cases in the literature presenting invasive breast cancer of the breast accompanying GIST as a second primary tumor (6, 7). Subash et al. (6) presented a case with GIST in which Position Emission Computed Tomography (PET-CT) demonstrated an increased uptake in her left breast and breast biopsy proved an invasive ductal breast cancer. Obinna et al. (4) presented a case with GIST who developed an intramammary lymph node metastasis and intestinal metastasis. Our case presentation seems to be the first in literature to demonstrate a breast metastasis of GIST. CD117 is expressed in Phyllodes tumors (PT) of breast (8). This study showed weak staining with CD117 in 5 of 17 PTs (8).

Gastrointestinal stromal tumors rarely can contain signet-ring-like components. Epithelioid type GISTs comprising signet-ring-like cells must be differentiated from invasive lobular cancers of breast in terms of diagnosis. In the study of Yared et al. (9) CD117 was applied to the tissue samples obtained from 21 normal breast epithelia, 24 benign breast lesions, 29 in situ breast carcinomas and 41 invasive carcinomas. Positive staining was demonstrated in 100% of normal breast epithelia, 88% of benign breast lesions, 20% of in situ carcinomas and 18% of invasive breast carcinomas. Of the 6 invasive breast cancers which stained strong positive, two were lobular, one was ductal and one was signet ring cell cancers. Also, CD117 positivity was shown in a case of gastric epithelioid GIST presented in the literature, which later presented an axillary mass and ER and GCDFP-15 positivity in breast and gastric samples resulting in the diagnosis of primary lobular carcinoma of the breast and a gastric metastasis (10).

Therefore, especially before diagnosing epithelioid-type stromal tumors, lobular and signet ring cell carcinomas of the breast must be differentiated by immunohistochemical and radiological examinations. Studies concerning GIST in the literature commonly present liver, lung and bone metastases. Hereby, we presented the first case of GIST metastasizing to breast, which we think is a very extraordinary condition and discussed according to the literature. It must be kept in mind that demonstration of a spindle cell neoplasia can either belong to a primary tumor or a metastasis. Therefore, CD117, which is stained both in GIST and most spindle cell bearing conditions of the breast such as Phyllodes tumors, and DOG1 staining studies must be added to foresee GIST metastasis.

References